# Optimizing A Miniaturized and Integrated Continuous Glucose Monitoring Platform

> **NIH NIH SB1** · INTEGRATED MEDICAL SENSORS · 2024 · $495,495

## Abstract

PROJECT SUMMARY
The long-term goal of this project is to develop a scalable, user-friendly, continuous glucose monitoring
(CGM) system for better diabetes management. IMS has developed the world's smallest
electrochemical analyte sensing platform based on an application-specific integrated circuit (ASIC)
using Complementary Metal-Oxide Semiconductor (CMOS) technology. This design offers some unique
advantages due to its active digital sensor (compared to passive analog sensors in current leading
CGMs) including extreme miniaturization, on-chip integration of multiple sensors and processing
electronics, improvement in signal-to-noise (SNR) ratio (thus improving hypoglycemia accuracy), and
on-chip temperature calibration (improve accuracy, reliability by confirming the sensor is in the tissue,
and performing on-site temperature calibration during sickness, exercise, and sleep). Moreover, the
system uses extremely scalable semiconductor and flexible electronics manufacturing methods,
increasing lot sizes by > 50,000x (simplifying factory calibration) and reducing cost (improving
affordability and broadening usage). The proposed system is named CGM+ since it goes beyond just
glucose monitoring (v1 measures glucose and temperature, v2 will measure glucose, ketones,
temperature, and pH). Hence, the design is highly innovative.
We have demonstrated the function of the CGM+ platform in humans in a First-In-Human (FIH)
feasibility study in Phase II. Recently, we verified the feasibility of system operation for 14 days in a
second human study (ongoing).
Our objective in this CRP grant is to optimize the manufacturing and the quality framework to enable
larger human studies, paving the way towards enabling an FDA IDE for approval trials.
This work is significant as it will catalyze the commercialization of the first CGM+ system capable of
the smallest needle insertion (28-gauge needle) that can work for a long time (>14 days) with factory
calibration (no finger sticks). After the first approval, this system can be extended to include other
analytes (e.g., ketones, insulin, glucagon) without increasing its size, owing to the on-chip integration
of multiple sensors.
The team includes original inventors of the core technology from the California Institute of Technology
(Dr. Nazari, Dr. Rahman, Mr. Sencan), a seasoned and respected researcher in electrochemical sensor
technology (Bill Van Antwerp, former CSO of Medtronic MiniMed), regulatory and IP expert (John
Heithaus, JD), commercialization expert (Mr. Paul Strasma, former CEO of Capillary Biomedical which
was recently acquired by Tandem Diabetes), clinical expert (Dr. Alan Marcus, MD; former Chief Medical
Officer of Medtronic Diabetes), and a biosensors and biomaterials expert (Dr. Natalie Wisniewski, Ph.D.,
former CTO of Profusa, Inc.).

## Key facts

- **NIH application ID:** 11071885
- **Project number:** 1SB1DK142387-01
- **Recipient organization:** INTEGRATED MEDICAL SENSORS
- **Principal Investigator:** Muhammad Mujeeb-U-Rahman
- **Activity code:** SB1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $495,495
- **Award type:** 1
- **Project period:** 2024-09-16 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11071885

## Citation

> US National Institutes of Health, RePORTER application 11071885, Optimizing A Miniaturized and Integrated Continuous Glucose Monitoring Platform (1SB1DK142387-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11071885. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*